Ranitidin: Béda antarrépisi

Konten dihapus Konten ditambahkan
Muthi'ah Zahra (obrolan | kontribusi)
Tidak ada ringkasan suntingan
Muthi'ah Zahra (obrolan | kontribusi)
Tidak ada ringkasan suntingan
Baris ka-110:
|specific_rotation=
}}
'''Ranitidin''' téh salah sahiji ubar golongan antagonis reseptor H2 histamin,<ref name=":0">{{Cite web|url=https://www.drugbank.ca/drugs/DB00863|title=Ranitidine|website=www.drugbank.ca|accessdate=2020-06-30}}</ref> nyaéta ubar nu dipaké pikeun ngubaran kaayaan nu aya patalina jeung [[asam lambung]] dina [[beuteung]].<ref name=":1">{{Cite web|url=https://www.drugs.com/ranitidine.html|title=Ranitidine: Uses, Dosage, Side Effects, Warnings|website=Drugs.com|language=en|accessdate=2020-06-30}}</ref> Miboga fungsi pikeun nyingkahan sarta ngungkulan rasa panas dina beuteung, [[maag]], jeung kasakit lianna nu disababkeun ku tukak lambung.<ref name=":2">{{Cite web|url=https://hellosehat.com/obatan-suplemen/obat/ranitidine/|title=Ranitidine : Fungsi, Dosis, Efek Samping, Cara Pakai|website=Hello Sehat|language=id-ID|accessdate=2020-06-30}}</ref> Ubar ieu dipikawanoh ogé salaku Zantac, sadia dina sababaraha bentuk kaasup tablét, jeung injéksi.<ref name=":3">{{Cite web|url=https://www.alodokter.com/ranitidin|title=Ranitidin|website=Alodokter|accessdate=2020-06-30}}</ref><ref name=":4">{{Cite web|url=https://www.webmd.com/drugs/2/drug-4091-4033/ranitidine-oral/ranitidine-liquid-oral/details|title=Drugs & Medications|website=www.webmd.com|language=en|accessdate=2020-06-30}}</ref>
 
== Kagunaan ==
Baris ka-160:
* [[Atazanavir]], pamakéan ubar ieu jeung ranitidin bisa nyababkeun panyerapan atazanavir nu jadi ngurangan éféktivitasnya,<ref>{{Cite web|url=https://www.drugs.com/drug-interactions/atazanavir-with-ranitidine-272-0-1991-0.html|title=Atazanavir and ranitidine Drug Interactions|website=Drugs.com|language=en|accessdate=2020-06-30}}</ref>
* [[Dasatinib]], nginum dasatinib babarengan jeung ranitidin ilaharna mah teu dianjurkeun. Ranitidin bisa ngaganggu penyerepan dasatinib kana jero getih nu bisa nyababkeun ubar ieu kurang éféktif dina ngubaran [[kanker]],<ref>{{Cite web|url=https://www.drugs.com/drug-interactions/dasatinib-with-ranitidine-787-0-1991-0.html|title=Dasatinib and ranitidine Drug Interactions|website=Drugs.com|language=en|accessdate=2020-07-01}}</ref>
* [[Loperamid]], pamakéan ranitidin jeung loperamid bisa sacara signifikan ninngkatkeun kadar loperamide dina getih. IIeu bisa nyababkeun komplikasi serius sarta miboga poténsi fatalparna kayaning ratug jantung jadi teu taratur sarta eureunna jantung, utamana mun dosis nu dipaké leuwih ti dosis nu dianjurkeun, <ref>{{Cite web|url=https://www.drugs.com/drug-interactions/loperamide-with-ranitidine-1482-0-1991-0.html|title=Loperamide and ranitidine Drug Interactions|website=Drugs.com|language=en|accessdate=2020-07-01}}</ref>
* [[Neratinib]], kucara ngurangan tingkat keasaman dina beuteung, ranitidin bisa ngaganggu panyerepan neratinib jeung ngurangan éféktivitasna,<ref>{{Cite web|url=https://www.drugs.com/drug-interactions/neratinib-with-ranitidine-3827-0-1991-0.html|title=Neratinib and ranitidine Drug Interactions|website=Drugs.com|language=en|accessdate=2020-07-01}}</ref>
* Salian ti interaksi jeung ubar lian, ranitidin ogé bisa nyababkeun interaksi jeung kaayaan kaséhatan pasén, contona panyakit ginjal, haté sarta ''prophyria''.<ref name=":3" /><br />
 
== Éfék samping ==
Éfék samping mangrupakeun hiji éfék nu teu dipiharep tina ubar. Éfék samping ieu bisa mangrupa-rupa di sababaraha jalma gumantung kana kaayaan panyakit, umur, beurat awak, jinis kelamin, étnis, jeung sababaraha kaayaan kaséhatan lianna. Sababaraha éfék samping nu ilahar karandapan sanggeus nginum ranitidin kayaning sebel jeung utah, nyeri sirah,<ref>{{Cite web|url=https://www.farmasi-id.com/ranitidine/|title=Ranitidine {{!}} Kandungan, Indikasi, Efek Samping, Dosis, Obat Apa|website=Farmasi-id.com|language=en-US|accessdate=2020-07-01}}</ref> [[insomnia]], [[vértigo]], [[ruam kulit]], [[konstipasi]], [[diaré]].<ref name=":4" /> Tapi mun ngarandapan éfék samping nu leuwih parna kayaning [[nyeri beuteung]], teu hayang barangdahar, cikiih kiruh, [[kulit]] babari geuneuk, ratug [[jantung]] nu naék turun teu taratur, [[buuk]] murudul, linglung, halusinasi, [[panyakit konéng]], gera tepungan dokter keur pamariksaan nu leuwih serius.<ref name=":3" />
 
== Kontrovérsi ==
Dina tanggal 13 Séptémber 2019, FDA ngabéwarakeun yén tés saacanna manggihan kandungan N-nitrosodimethylamine atawa NDMA di ranitidin, ubar maag nu ilahar dipaké.<ref>{{Cite web|url=https://www.health.harvard.edu/blog/popular-heartburn-drug-ranitidine-recalled-what-you-need-to-know-and-do-2019092817911|title=Popular heartburn drug ranitidine recalled: What you need to know and do|last=ScD|first=Joshua Gagne, PharmD|website=Harvard Health Blog|language=en-US|accessdate=2020-06-30}}</ref><ref>{{Cite web|url=https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market|title=FDA Requests Removal of All Ranitidine Products (Zantac) from the Market|last=Commissioner|first=Office of the|website=FDA|language=en|accessdate=2020-06-30}}</ref> Lian ti éta, Badan Pemeriksa Obat dan Makanan (BPOM) geus ménta perusahaan farmasi pikeun ngeureunkeun sarta narik ubar Ranitidin kusabab ngandung N-Nitrosodimethylamine atau NDMA.<ref>{{Cite web|url=https://www.kompas.com/tren/read/2019/11/21/194642265/ranitidin-dapat-diedarkan-kembali-ini-penjelasan-bpom|title=Ranitidin Dapat Diedarkan Kembali, Ini Penjelasan BPOM Halaman 2|last=Media|first=Kompas Cyber|website=KOMPAS.com|language=id|accessdate=2020-06-30}}</ref>
 
NDMA mangrupakeun zat nu sabenerna teu bahaya mun diinumm dina batas normal, ngan BPOM manggihan kandungan diluhureun batas normanormal nu nyababkeun NDMA jadi miboga sifat [[karsinogenik]] atawa bisa micu kanker, ku kituna ubar ieu geus kungsi ditarik tina pasaran. Tapi teu kungsi lila, BPOM méré ijin deui pikeun ubar ieu dipasarkeun, kusabab sanggeus dilakukeun panalungtikan ngeunaan ambang batas normal batas cemaran N-Nitrosodimethykamine (NDMA) nu kakandung dina ranitidin. NDMA ogé dipiwanoh salaku pencemar lingkungan nu aya dina cai, [[daging]], [[sayuran]], jeung produk susu. Studi global mutuskeun yén nilai ambang batas cemaran NDMA di ijinkeun nyaéta 96 mg/sapoé. Mun diinum diluhureun batas normal unggal poe dina jangka wkatu nu lila, miboga poténsi karsinogenik.<ref>{{Cite web|url=https://www.cnnindonesia.com/nasional/20191008165103-20-437820/ranitidin-obat-asam-lambung-yang-diduga-picu-kanker|title=Ranitidin, Obat Asam Lambung yang Diduga Picu Kanker|website=nasional|language=id-ID|accessdate=2020-06-30}}</ref>
 
== Tutumbu luar ==
 
* [https://www.drugs.com/sfx/ranitidine-side-effects.html Éfek Samping Ranitidin]
* [https://www.drugs.com/drug-interactions/ranitidine.html Interaksi Ranitidin]
 
== Rujukan ==